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Abstract:  A comprehensive synthetic review of the pederin family of cytotoxins, including 
pederin, the mycalamides, and psymberin, is presented.  A number of approaches to the synthesis 
of these molecules is covered, including pederic acid, the tetrahydropyranyl ring of pederin, the 
trioxadecalin ring of the mycalamides, and psymberin fragments.  Coupling strategies for these 
compounds are also summarized.  An overview of biological activity at various positions of 
mycalamide A, as well as some analogs, is given. 
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1. Introduction 
Psymberin (Psammoncinia, symbiont, pederin), a potent cytotoxin, was recently isolated 
from the Psammoncinia sponge off the coast of Papua New Guinea.1  This compound showed a 
strong structural resemblance to several other cytotoxins that had been previously isolated, 
including pederin,2 the mycalamides,3 the onnamides A-F,4 and theopederins A-L.5  The general 
structures of pederin and mycalamides A and B are shown in Figure 1. 
Figure 1  Pederin and Mycalamides A and B 
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Note that these cytotoxic compounds contain the same left portion, known as pederic acid.   
The structure of psymberin is shown in Figure 2. 
Figure 2  Psymberin 
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The most notable common feature of the compounds in this family is the presence of the N-acyl 
aminal portion bridging the left and right fragments.  The molecules above have been numbered 
1 
 to highlight the similarity of the structures:  C4 to C14 of pederin and mycalamide correspond to 
C2 to C16 of psymberin. 
The scope of this paper will be limited to pederin, the mycalamides, and psymberin.  All 
of these cytotoxins show both anticancer and immunosuppressant activity in nanomolar 
concentrations and have potential medical applications.6 
 
2. Isolation 
Pederin was first isolated in 1949 from Paederus fuscipes, a Japanese beetle known for 
its severely irritating bite.2a  This compound was later characterized and identified as pederin.2b 
The mycalamides were isolated from the Mycale sponge off the coast of New Zealand in 
the Otago harbor in 1988.3a  Using gel permeation and various chromatographic techniques, 
Munro and others successfully extracted the active metabolite and identified it as mycalamide A.  
Several years later, mycalamide B was also identified as part of another collection of this 
sponge.3b  More recently, mycalamides C and D were isolated by the same group of researchers 
in 2000.3c 
Psymberin was also isolated from a marine sponge, Psammoncinia, from the Papua New 
Guinea waters.1,7  Although the extracts of this sponge were known to show anti-tumor activity, 
psymberin, the compound responsible for this activity, was not identified until 2001. 
 
3. Biosynthesis 
Early work by Cardani et. al. suggested that pederin is derived from polyketide 
biosynthesis.8  Recent studies involving gene cloning of the symbiont bacterium established the 
structure of the series of genes that form pederin.9  The proposed biosynthetic pathway is shown 
in Figure 3. 
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 Figure 3  Pederin Biosynthetic Pathway 
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The ped F gene is a polyketide synthase (PKS) gene, as predicted in the earlier work by Cardani. 
The current theory is that these cytotoxins are produced by symbiotic bacteria in both the 
Paederus beetle and the various sponges.9b 
Unfortunately, the bacteria responsible for pederin production have not yet been 
successfully cultured, and these compounds are isolated in very small quantities from each 
source.  For this reason, a need for a viable synthesis is desirable.  A summary of synthetic 
approaches are presented in detail in the paragraphs that follow. 
 
4. Synthesis: Pederic Acid 
The structure of pederic acid, a subunit common to pederin and mycalamides A and B, is 
shown in Figure 4. 
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 Figure 4  Pederic Acid 
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Many synthetic approaches to this molecule have been published by various research groups. 
 To organize the large number of syntheses of pederic acid and its derivatives, the 
schemes have been arranged based on the nature of the starting materials.  The work with chiral 
starting materials is presented first, leading up to the most efficient synthesis.  Then the schemes 
involving chiral reagents are presented. 
Matsumoto’s group used trans-butene oxide in their synthesis of pederin (Figure 5).10  
The synthesis of the bromomethyl benzoate 1 was originally published in 1978 in a Ph.D. thesis.  
The completion of the synthesis proceeded through a series of standard transformations to form 
the phenylselenide product 2. 
Figure 5  Matsumoto’s Pederic Acid Precursor Synthesis 
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The stereoselectivity of the synthesis was good, yielding the 7-(S) alcohol in a 5:1 diastereomeric 
ratio, but the scheme was very lengthy. 
Extensive work has also been done by Kocienski to construct pederin.11  The group’s 
most recent synthesis of the pederic acid precursor 4 is shown below (Figure 6).12 
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 Figure 6  Kocienski’s Pederic Acid Analog Synthesis 
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The final product was later lithiated for addition to the trioxadecalin ring, an approach pioneered 
by this group.13  Formation of the double bond from the phenylselenylmethyl substituent at the 4-
position (pederin numbering) was completed after coupling with the right half, as described later. 
 An advantage of this work was the very high diastereoselectivity of the cuprate 1,4-
addition and allylation reactions that formed 3.  However, the synthesis was still rather long, 
requiring seventeen steps. 
Recently, Hoffmann and others made a protected pederic acid from D-mannitol (Figure 
7).14  The first product, 1,3:4,6-di-o-benzylidene-D-mannitol 5, was first synthesized by Baggett 
and Stribblehill a few years prior to this publication.15  Notable features included an acid-
catalyzed cyclization to form the tetrahydropyranyl ring of 8 and a Ley oxidation of the C8 
primary alcohol to the aldehyde 9.  Although the tin chloride-mediated reaction of 6 provided the 
5 
 R isomer in a 10:1 diastereomeric ratio, this stereocenter was eliminated by the oxidation in the 
next step. 
Figure 7  Hoffmann’s Pederic Acid Analog Synthesis 
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D-mannitol provided the proper stereochemistry at C7, avoiding the hassles encountered by 
several other approaches.  The synthesis involved twelve steps, which was significantly shorter 
than Kocienski’s scheme. 
Meinwald also used trans-butene oxide 10 to make a racemic mixture of pederamide 15, 
the amide equivalent of pederic acid.  The thioacetal-protected lactone 11 in Figure 8 was made 
using a series of cyclization reactions.16 
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 Figure 8  Meinwald’s Pederamide Synthesis 
O
Li
DMSO, 77%
OH 1) n-BuLi, THF, -40°C
2) CO2; HCl-H2O, 56%
OH
CO2H
H2, 5% Pd-BaSO4
quinoline, MeOH
OH
CO2H
distillation
O O
1) CH3NO2,
    Triton-B, 88%
2) NaOMe, RT;
H2SO4
MeOH, -35°C
98% for 2 steps
O
OMe
O
OMe
1) HCl gas
    CHCl3, -35°C
2) HSCH2CH2SH
    RT, 96% for 2 steps
O O
S S
12, RLi, THF,
-75°C, 84%
O
S S
HO
OEt
O
O
OMe
1) HCl, THF
2) P2O5
    acetone, 81%
O
S S
O
O
O
OEt
1) HgO, HgCl2
    MeCN-H2O
    62°C, 92%
2) NaBH4, EtOH, 0°C
    quantitative
O
O
O
O
OEt
HO
2) HCl, MeOH
O
MeO OH
OMe
O
SeAr
1) H2O2
2) Heat
    52% for 2 steps
O
MeO OH
OMe
O
NH3, MeOH
100°C, sealed tube
O
MeO OH
NH2
O
OMe
O
OEt
O
12
10
11 13
15
1) o-NO2PhSeCN
    (n-Bu)3P
    THF, 94%
14
 
The chain was then attached via addition to the lactone carbonyl to form 13.  Oxidation of the 
arylselenide 14 to create the exocyclic double bond formed methyl pederate, which was easily 
converted into pederamide.  This synthesis was rather extensive with sixteen steps, and the 
stereoselectivity was poor. 
The same starting material was used by Trost’s group to construct an enantiomer of 
pederic acid 19 as part of a formal synthesis of (-)-mycalamide A,17 as shown in Figure 9. 
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 Figure 9  Trost’s Pederic Acid Synthesis 
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A key feature of this synthesis was the ruthenium catalyzed coupling of alkyne 16 and alkene 17, 
which allowed attachment of the chain at an early stage.  The synthesis was done in eleven steps, 
but there was no selectivity for the dihydroxylation of 18. 
In their first published paper on this topic, Toyota et. al. used a silylmethyl radical 
cyclization of 21 to form a heterocyclic ring starting from a chiral Evans aldol derivative 20 as 
shown in Figure 10.18 
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 Figure 10  Toyota’s Partial Pederic Acid Synthesis 
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This approach is very interesting, but the final steps for the conversion of the cyclization product 
22 to pederic acid were not provided. 
Several years later, the same group implemented a palladium catalyzed reaction to form 
the THP ring via an intramolecular cyclization.19  Once the allyl ether 23 was obtained, the stage 
was set to employ the palladium-catalyzed cyclization.  The synthesis is summarized in Figure 
11. 
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 Figure 11  Toyota’s Methyl Pederate Synthesis 
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The authors discovered that the selectivity of the lactone formation depended on both the 
palladium catalyst used as well as the solvent.  Notably, the 7-(R) epimer of the final product 25 
10 
 was converted to the desired isomer by Collins oxidation and sodium borohydride reduction in a 
5:1 diastereomeric ratio, as described in their earlier work.20 
This scheme introduced new palladium chemistry as part of the synthesis, but it had 
several disadvantages.  The diastereomeric ratio of the Claisen condensation of 24 was 1:1, 
showing no selectivity.  Also, the synthesis was quite lengthy, requiring twenty steps initially, 
and two more for the C7 epimerization. 
The Roush group completed several pederic acid syntheses.21  Their most successful 
contribution involved a diastereoselective aldol reaction of 26 to introduce the C7-(S) 
stereochemistry using a chiral acyloxazolidinone 27 (Figure 12).22  The enol borane formed in 
this reaction provided the syn-aldol in high yield (79% for the aldol reaction).   
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 Figure 12  Roush’s Methyl Pederate Synthesis 
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27R  
This work required fifteen steps (five fewer than Toyota) and provided good stereoselectivity.  
However, a shorter sequence was desirable. 
A considerable amount of work has been done by the Nakata group.  After first 
synthesizing (+)-benzoylselenopederic acid, described in an earlier paper,23 this group developed 
a very efficient synthesis of protected methyl pederate 30 from the L-valine derived 
propionimide 28.24  The synthesis is summarized in Figure 13.25 
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 Figure 13  Nakata’s Methyl Pederate Synthesis 
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30  
Stereoselectively controlled steps included the Evans aldol reaction of 28, which proceeded with 
very high stereoselectivity, and the intramolecular Claisen condensation of 29, which gave a 
single isomer.  Overall, the synthesis proceeded through only nine steps and gave a 26% overall 
yield.   
Recently, Rawal et.al. completed a synthesis of a pederic acid derivative using the chiral 
homoallylic alcohol 31 (Figure 14).26  The group utilized a Heck reaction for the cyclization of 
the tetrahydropyranyl ring to form 33. 
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 Figure 14  Rawal’s Pederic Acid Synthesis 
OH
O
O
HO
O
Ph
O O
O
Ph
O O
O
Ph
MeO
O
MeO OTES
OH
O
MeO OBz
O
OH
+
1) EDC, DMAP
    CH2Cl2, 91%
2) Cp2TiMe2
    PhMe
    80°C, 85%
PdCl2, benzoquinone
  MeOH, (MeO)3CH
propylene oxide
THF-DMF
78%, 5.7:1 R:S
1) Na, NH3
    EtOH, 93%
2) TESCl, i-Pr2EtN
    CH2Cl2, 93%
2) PDC, DMF, 83%
1) BzCl, DMAP
    i-Pr2NEt
    CH2Cl2, 94%
31
33 34
32
 
The synthesis improved on Nakata’s work, entailing only seven steps from the protected glyceric 
acid 32 and provided the final product 34 in 35% overall yield. 
 
5. Synthesis: Psymberic Acid 
Psymberic acid is analogous to pederic acid, as it refers to the left carboxylic acid 
segment of psymberin (Figure 15). 
Figure 15  Psymberic Acid 
OOMe
OH
OH
 
The synthesis of this molecule typically requires seven to eight steps, as discussed below. 
Only three syntheses of this molecule have been published to date.  The first was done by 
Kiren and Williams using a protected dihydroxy aldehyde 35 as the starting material (Figure 
16).27 
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 Figure 16  Kiren and Williams’ Psymberic Acid Synthesis 
 
OH
OH
OMe O
O
O
O
O
O
OMe
OH
O
O
OMe
OTBDMS
OH
1) (COCl)2, DMSO
    CH2Cl2, -78°C, 98%
2) NaOCl2, NaH2PO4
    2-methyl-2-butene
    t-BuOH-H2O,
    0°C to RT, 80%
 CH2C(CH3)CH2MgCl
THF, -78°C to RT NaH, MeI
74%, 4:3 dr
1) AcOH-H2O
    RT, 93%
2) TBDMSCl, DMF
    imidazole, RT, 88%
3) HF-pyr, RT, 73%
THF, RT, 91%
35
4
5
 
Prior to this work, assignment of the C4 and C5 stereochemistry shown in Figure 16 was based 
on homology with other molecules in the pederin family.  These researchers proposed that the 
amide side chain configuration was the anti-isomer based on NMR data of the product.  This 
synthesis was a good first approach to psymberic acid; however, the stereoselectivity at C4 was 
poor (4:3 S:R) 
De Brabander et. al. reported a similar synthesis of psymberic acid using the same 
starting material as Kiren and Williams (Figure 17).28 
Figure 17  De Brabander’s Psymberic Acid Synthesis 
 
O
O
O
OH
OHOMe
OHOMe
OBz
OOMe
OBz
OH
1) (-)-(Ipc)2BOMe
    CH2CMeCH2Li
    Et2O, -78°C, 97:3 dr
2) NaH, MeI, THF
3) PPTS, MeOH-H2O
    50°C, 62% for 3 steps
1) TBDMSCl
    imidazole
    CH2Cl2
2) BzCl, pyr
3) HCl-H2O
    90% for 3 steps
1) Dess-Martin
    periodinane
    CH2Cl2
2) NaClO2, NaH2PO4 
    2-methyl-2-butene
    t-BuOH-H2O
    87% for 2 steps
4
36
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 Additionally, the paper proposed a complete synthesis of psymberin utilizing a chiral 
methallylating agent, the remainder of which will be presented later. This work also established 
that psymberin and irciniastatin A, isolated by Pettit and others,7 are identical compounds. 
Although the synthesis required an additional step, the 97:3 diastereomeric ratio was very 
high at C4 of 36.  The yield was also improved to 48.5% from the 31.5% reported by Kiren and 
Williams. 
Recently, Floreancig et. al. published experiments that further elaborated on the Kiren 
and Williams amide side chain findings.  Their synthesis of psymberic acid using the D-serine 
derivative 37 is shown in Figure 18.29 
Figure 18  Floreancig’s Psymberic Acid Synthesis 
 
MeO
O
OH
OH MeO
O
PMBO
OTBDPS
O
PMBO
OTBDPS
PMBO
OTBDPS
OMe
PMBO
OH
OMe O
1) TBDPSCl
    imidazole
   -42°C, 74%
2) BnOC(=NH)CCl3
    BF3.THF, C6H12
    0°C to RT, 76%
DIBALH
CH2Cl2, -78°C
1)TMSCH2C(Me)CH2
    BF3.THF, CH2Cl2, -78°
    56% for 2 steps, 4:1 dr
2) MeOTf, 2,6-(t-Bu)2pyr
    CH2Cl2, 86%
1) TBAF, THF, 76%
2) SO3.pyr, DMSO, Et3N;
    NaOCl2, NaH2PO4
    2-methyl-2-butene
    t-BuOH, H2O, 77%
37
5
4
 
To establish the stereochemistry, four variants of this molecule were synthesized with 
varying stereochemistry at the 4 and 5 positions.  The products were exposed to acid degradation 
and compared to the degradation product of the natural compound.  The configuration was 
determined to be 4-(S), 5-(S). 
16 
 The yield was 16% for this sequence, the stereoselectivity was 4:1 at C4, and the 
synthesis required only seven steps. 
 
6. Synthesis: THP Ring 
Synthesis of the tetrahydropyranyl ring of pederin, commonly referred to as the right half 
of the molecule, also presents a challenge for researchers.  The structure is shown in Figure 19. 
Figure 19  THP Ring 
     
O
OH
OMe
N
H OMe
OMe
 
Strategies for constructing this portion of the molecule date back almost three decades, and many 
researchers have developed unique syntheses, as demonstrated below. 
Matsumoto published some early work establishing a total synthesis of (+)-pedamide 
using the hydroxy aldehyde 38.30  The ring of diol 41 was formed through an acid catalyzed 
cyclization, followed by construction of the amide functionality of 42 (Figure 20). 
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 Figure 20  Matsumoto’s THP Ring Synthesis 
OH
O
OH
OH
+
PTSA, PhH
 reflux
1) PCC, CH2Cl2, RT
2) AllylMgBr
    Et2O, RT
3) CrO3, H2SO4
    acetone, 0°C
    51% for 4 steps
1) LAH, Et2O
    PhMe, -123°C
    98%, 87:13 dr
2) BnCl
    t-AmONa
    DMSO, RT
1) m-CPBA
    CH2Cl2, RT
2) NaOMe
    MeOH, RT
3) CrO3, pyr
    CH2Cl2, RT
    76% for 4 steps
1) Li(Ot-Bu)3AlH,     
    Et2O, -78°C, 95% S
2) MeI, NaH, PhH
    reflux, 93%
1) HCl, acetone
    reflux
2) AllylMgBr
Et2O, RT
78% for 2 steps
1:1 R:S
3) Na, NH3
    -78°C, 74%
HO
OMe
OMe
OH
BnO
OMe
OMeO
O
BnO
OMe
OO
O
BnO
O
O
O
O
O
HO
O
O
1) m-CPBA
    CH2Cl2, RT
2) PTSA, PhH, reflux
    86% for 2 steps
OMe
OMe
O
O
OH
1) CrO3, H2SO4
    acetone, RT
2) CH2N2, Et2O, RT
3) NaBH4, EtOH, -78°C 
    68% for 3 steps, 1:1 dr
OMe
OMe
O
OH
OH
MeO
1) BzCl, pyr
    RT, 94%
2) LDA, THF
    -78°C; HOAc
    54% S, 12% R
OMe
OMe
O
O
OBz
MeO
1) Et3N, H2O
    MeOH, RT
2) SOCl2, DMF
    CH2Cl2, reflux
3) NH3, CH2Cl2, 0°C
    79% for 3 steps
OMe
OMe
O
O
OBz
H2N
38
39
41
42
40
 
A key step in this scheme was the asymmetric reduction of the ketone 39 to form the 
alcohol with high stereoselectivity.  On the downside, the synthesis was very lengthy, and 
stereoselectivity was low for the allylation intermediate 40. 
18 
 Meinwald began his synthesis of the THP ring using cyclopentanone and the 
dibromoketone 43 (Figure 21).31  A Horner-Emmons reaction was used to attach the side chain 
of 45, and a series of oxidations and reductions were used to form the final aldehyde 47. 
Figure 21  Meinwald’s THP Ring Synthesis 
O
Br Br
O
O
1) Zn, HOAc, 50%
2) L-selectride+
HHO
O3, MeOH;
Me2S
O
OO
OH
1) CrO3
2) H+, MeOH
O
OH
MeO
O
OMe
OMe
PTSA, PhH
reflux
1) KOt-Bu
    t-BuOH
2) Red-Al
1) NaH, BzBr
2) HSCH2CH2SH
    BF3.Et2O
O
OH
OBz
S
S
1) Acetylation
2) HgO, HgCl2
3) 44, Horner-Emmons
O
OAc
OBz
OMe
OMe
O 1) NiCl2
    NaBH4
2) LAH
3) NaH, MeI
O
OH
OBz
OMe
OMe 1) Acetylation
2) H2, catalyst
3) CrO3
.pyr
O
OAc
O
OMe
OMe
MeO
P
OMe
O
MeO
OMe
O
44
43
46 47
O
O
OH
OMe
O
O
O
OMeMeO
45
 
The final aldehyde was a non-dehydrated version of pederenal, an acid hydrolysis product of 
pederin. 
Meinwald’s work provided a unique tricyclic approach to forming the right side of 
pederin.  However, this synthesis was also lengthy, and the diastereomeric ratio after formation 
of the C17 methoxy group of 46 was low. 
19 
 Following an earlier attempt,32 Nakata’s group synthesized (+)-benzoylpedamide using a 
SmI2-mediated Reformatsky reaction on 48, as shown in Figure 22.33 
Figure 22  Nakata’s THP Ring Synthesis 
OH
OH
O
O
O
O
O
O
TBDMSO
1) BH3
.SMe2, THF
2) PTSA, acetone
3) Swern oxidation;
    Ph3P=CHCO2Et
    81% for 3 steps
2) O3, THF
    -78°C; Me2S
OH
TBDMSO
OH
O
TBDMSO
1) HCl, THF
2) TBDMSCl, pyr
    99% for 2 steps
1) Me2CBrCOBr
    Et3N, CH2Cl2, 100% SmI2, THF, 0°C
85% for 2 steps
1) DIBALH
    CH2Cl2, -78°C
2) BzCl, pyr
    89% for 2 steps
O
TBDMSO
OBz
OBz
O
O
OBz
OMe
OMe
H2N
PyBOP, HOBt
NH4Cl, i-Pr2Et 
DMF, RT 
86% for 3 steps
OsO4, (DHQ)2PYR
K3Fe(CN)6, K2CO3
t-BuOH-H2O, 0°C
68% S, 22% R
MeSO3NH2
O
TBDMSO
OBz
O
TBDMSO
OBz
OH
OH
1) NaH, MeI
    DMF, RT
2) CrO3, H2SO4
    acetone
O
Br
O
OH
1) AllylTMS, BF3.Et2O
    TMSOTf, MeCN, RT
2) TBDMSCl, imidazole
    100% for 2 steps
O
O
OBz
OMe
OMe
HO
OEt
O
OEt
O
48
49 50
51
 
Reduction of the lactone 49 followed by selective allylation of 50 allowed efficient attachment of 
the side chain.  This synthesis was shorter than the previous two schemes, completed in sixteen 
steps with a 35% overall yield, but the diastereomeric ratio of the dihydroxylation of 51 was low. 
Kocienski’s contributions date back more than two decades.34  In his latest publication,12 
ethyl isobutyrate 52 was used as the achiral starting material.  The intermediate 54 was quite 
20 
 versatile, as it can be used to make both the THP ring of pederin as well as the trioxadecalin ring 
of the mycalamides.  The final steps of the synthesis created the amide 55 for coupling (Figure 
23). 
Figure 23  Kocienski’s THP Ring Synthesis 
O
OEt
TMSO
OEt
O
EtO
HO
N
BH
OO
Tos
OO
O
LDA, TMSCl
THF, 91% THF, -78°C
95%, 97:3 er
1) Ac2O, Et3N, DMAP
    CH2Cl2, RT, 76%
2) LDA, THF
    -78°C, 78%
53, Cl(CH2)3CHO
54
ClCl
O
OH
NC
1) TMSCN, TMSOTf
    CH2Cl2, 0°C
    92%, 99:1 dr
2) NaBH4, CeCl3
.7 H2O
    MeOH, -95 to -60°C
    99%, 30:1 dr
1) TBDMSOTf
    2,6-lutidine, CH2Cl2
    0 to 5°C, 99%
2) PhSeNa
    EtOH, 91%
O
OTBDMS
NC
1) NaIO4
    MeOH-H2O, RT
2) Et3N-PhMe, heat
    96% for 2 steps
O
OTBDMS
NC 1) Sharpless AD
    78%, 3:2 dr
2) NaH, MeI, 18-c-6
    THF, RT, 91%
O
OTBDMS
O
H2N
H2O2, K2CO3
 EtOH-H2O
   RT, 87%
OMe
OMe
O
OTBDMS
NC
OMe
OMe
SePhCl
53
52
55  
 This work provided very high diastereoselectivity for cyanation and reduction of 54, but 
the synthesis still consisted of seventeen steps.  
Hoffmann reported a shorter synthesis of benzoylpedamide from diester 56, derived from 
malic acid.35  Chiral allylboronate compounds 58 and 60 were used to control diastereoselectivity 
of the chain extensions (Figure 24). 
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 Figure 24  Hoffmann’s THP Ring Synthesis 
 
O
OHO
OMe
MeO
O
OMe
O
B
Cl
O
O
HO
BnO
O
BnO
OH
HO
OH
O
OBz
O
H2N OMe
OMe
OBzO
OBz
OMe
OMe
OMe
OMe
OMe
OMeCl
OMe
OMe
OMe
OMe
OMe
OMe
OMe
OMe
B O
O
58 60
56
57
59
61
1) H3B
.SMe2
    NaBH4, THF
2) CH2N2
    SiO2, Et2O
    0°C, 80%
DIBALH
PhMe
-78°C, 83%
58
pet. ether
RT, 73%
87:13 dr
1) NaH, BnBr
    DMF, 76%
2) O3, CH2Cl2
    -78°C, 90%
RT, 95%
4:1 dr
60
pet. ether Li/NH3
THF, 86%
1) O3, CH2Cl2
    -78°C, 92%
2) BzCl
    DMAP, pyr
    0°C to RT, 77%
1) TMSCN, MeCN
    BF3
.OEt2
    97:3 dr, 98%
2) H2O2, K2CO3
    EtOH, RT, 74%
 
A major advantage of this work was that the use of malic acid provided the proper C17 
stereochemistry at the outset.  Also, high stereoselectivity was obtained for the allylboration 
reactions: 87% for the reaction of 58 and 80% for the reaction of 60.  This newer scheme 
produced benzoyl pedamide 61 in twelve steps, the fewest steps of the syntheses presented here.  
A negative point was that the diastereomeric ratios were not as high as Kocienski’s. 
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 7. Synthesis: Amido Trioxadecalin Ring System 
The amido trioxadecalin ring system of the mycalamides is analogous to the THP ring of 
pederin with an additional ring (Figure 25). 
Figure 25  Amido Trioxadecalin Ring System 
O
OMe
OR
O O
H2N
Mycalamide A: R = H
Mycalamide B: R = Me
OH
10
 
Note that the C10 aminal methoxy of pederin is now part of the second ring of mycalamide.  A 
number of researchers have published papers pertaining to this compound.  As with the pederic 
acid syntheses, the work below is organized from earlier work up to the most efficient synthesis. 
 The Kishi group published a synthesis of the right half of pederin that started with 62 and 
the second ring was constructed through acetalization of deprotected 63 (Figure 26).36 
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 Figure 26  Kishi’s Amido Trioxadecalin Ring Synthesis 
O
MeO OMe
OBn
1) Propargyl TMS
    TMSOTf, MeCN
O
OMe
OBn
MeO
OMe
2) Ozonolysis
3) Acetalization
    60% for 3 steps
1) H2, Pd(OH)2-C,
    EtOAc, RT
2) (HCHO)n
    HCl, 0°C
O
OMe
O
HO
O
1) MsCl, Et3N
    DMAP
    CH2Cl2, -60°C
2) n-Bu4NN3
    CH2Cl2
    -78°C to RT
    72% for 2 steps
    2:1 dr
O
OMe
O
N3
O
1) NaOH
    aq. p-dioxane, RT
2) 4-MeOC6H4(C6H5)2CCl
    i-Pr2EtN, CH2Cl2, RT
3) MeI, NaH, DMF, 75°C
4) PTSA, MeOH, RT
5) Ac2O, DMAP, CH2Cl2, RT
    76% for 5 steps
O
OMe
OO
N3
H2, Pd-C
O
OMe
OO
H2N
 EtOAc, RT
O
HO OH
OH
OH
OH
1) PMB(OMe)2
    PTSA
2) (n-Bu)2SnO;
    PTSCl, Et3N
O
MeO OMe
OH
OBn
OPMB
1) Swern oxidation
2) Wittig reaction
3) CH2N2, Pd(OAc)2
    Et2O, 0°C
4) H2, Pd(OH)2-C
    EtOAc, RT
5) TBDPSCl, imidazole
    CH2Cl2, RT
6) BnBr, NaH, THF, RT
7) TBAF, THF, RT
3) MeI, Ag2O
4) Na(Hg)
5) BnBr, NaH
6) NaBH3CN, TFA
O
MeO OMe
OBn
OH 1) Swern oxidation
2) Horner-Emmons
3) DIBALH, CH2Cl2, -78°C
4) H2, Rh-Al2O3, EtOAc, RT
5) o-O2NC6H4SeCN, P(n-Bu)3
    PhH, RT; m-CPBA
O
MeO OMe
OBn
1) OsO4
    N,N'-bis(2,4,6-trimethylbenzyl)- 
    (S,S)-1,2-diphenyl-
    1,2-diaminoethane
    CH2Cl2, -90°C, 6:1 dr
2) Carbonate formation
62
63
64
O
O
O
O
O
O
O
O
O
O
O
O
OMe
OAc
OMe
OAc
 
This group pioneered the synthesis of the trioxadecalin ring; however, the synthesis was very 
long with thirty-three steps, and the diastereoselectivity during formation of the second ring of 
64 was low. 
24 
 Nakata and his group have done several syntheses of the right half of mycalamide A.37  In 
1996, a synthesis involving a chiral starting material was published.38  The synthesis began with 
the transformation of (S)-pantolactone 65 into the epoxide 66, which was then converted to the 
triol 68 as shown (no diastereomeric ratio was provided for the allylation reaction of aldehyde 
67).  The triol was then cyclized and converted to the diacetal-methoxy compound 69.  The 
trioxadecalin ring was constructed from the allene 70 and converted to the amine as shown in 
Figure 27. 
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 Figure 27  Nakata’s Amido Trioxadecalin Ring Synthesis 
 
OO
HO
1) LAH
2) CSA, acetone
3) BnBr, NaH
4) AcOH-H2O
5) NaH, PTSCl
OBnO
OBnOH
HO
OH
1) CH2=CHMgBr, CuI
    THF, -20°C to RT, 89%
2) OsO4, (DHQ)2PHAL
    K3Fe(CN)6, K2CO3
    t-BuOH, H2O, 0°C
    90%, 2.45:1 dr
1) TBDPSCl
    imidazole
    DMF, RT
2) Me2C(OMe)2
    CSA, CH2Cl2, RT
    92% for 3 steps
OBnO
TBDPSO
O 1) H2, Pd(OH)2    THF, RT
1) AllylMgCl
    THF, 0°C
OHOHOH
TBDPSO
OO
TBDPSO
O
2) DMSO, (COCl)2
    CH2Cl2, Et3N
    -78°C to RT
2) AcOH-H2O
1) O3, MeOH, -78°C;
    Me2S, -78°C to RT
2) (MeO)3CH
    CSA, MeOH, RT
3) Me2C(OMe)2
    CH2Cl2, CSA, RT
65 66
6867
O
MeO OH
1) PDC
    CH2Cl2, RT
2) TBAF
    THF, RT
O
O
1) NaBH4
    CeCl3, MeOH
    -78°C to RT
2) KH, MeI
    THF, 0°C
O
OMe
1) m-CPBA
    MeOH, RT
2) m-CPBA
    CH2Cl2, RT
O
O
O
O O
O
O
AcO
AcO OMe
O
OMeO
OH
Ar O
1) K2CO3
    MeOH, RT
2) Ac2O
    pyr, RT
O
O
O
O
1) AcOH-H2O, 60°C
2) Ac2O, pyr, RT
    92% for 2 steps
69  
26 
 O
OAc
OAc
AcO OMe
O
OAc
OAc
OMe
Propargyl TMS
TMSOTf, MeCN
0°C, 76%
O
OH
OMe
1) K2CO3
    MeOH, RT
2) Im2CO, THF, RT
    91% for 2 steps
O
OMe
O O
N3
H2, Pd/C
EtOAc, RT O
OMe
O O
H2N
1) O3, CH2Cl2, -78°C;
    Me2S, -78 to 0°C
2) (CH2O)n, CSA
    CH2Cl2, 0°C
3) Ac2O, pyr, RT
4) TMSN3, TMSOTf
    MeCN, 0°C
    57% for 4 steps
OAc OAc
O
O
O
O
O
O
O
O O
70  
This scheme was proposed as a more useful way to produce the molecule on a larger scale 
compared to their previous syntheses.  However, the reaction scheme was also very lengthy, and 
the stereoselectivity was not very good for the Sharpless dihydroxylation. 
Toyota’s group created the trioxadecalin ring from the sugar D-mannitol 71 (Figure 28).39  
The primary step in this sequence is the TiCl4 catalyzed aldol condensation of 72 to form the 
hydroxyester 73.  The second ring of 74 was formed using a stereoselective oxypalladation, 
which provided the cis-trioxadecalin in high yield (83% for this step). To complete the N-acyl 
aminal functionality, the carbamate 76 was constructed as illustrated in the figure. 
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 Figure 28  Toyota’s Amido Trioxadecalin Ring Synthesis 
OH
OH
OH
OH
HO
OH
O
O
OBn
O
O
OBn
TBDPSO
OH
1) OsO4, NMO
    100%, 8:1 S:R
2) TBDPSCl, DMAP
    Et3N, 51%
OBn
TBDPSO
OH OH
O t-Bu
O
OBn
TBDPSO
O
O
O
OTMS
OMe
1) HOAc-THF-H2O
    55°C, 98%
1) (MeO)2CH2
    P2O5, 88%
2) DIBALH
    0°C, 99%
3) (COCl)2, DMSO
    Et3N, -78 to -40°C
OBn
TBDPSO
O O
OH O
OMe
2) t-BuCOCl
    pyr, 89%
 CH2Cl2, 63%
1) NaH, MeI
    0°C to RT, 95%
2) DIBALH, 0°C, 100%
3) SO3
.pyr, DMSO
    Et3N, 97%
1) Ph3PMeBr, BuLi
    0°C to RT, 100%
2) Liq. NH3, Li, -78°C
3) DDQ
    74% for 2 steps
4) PdCl2, CuCl, O2
    DMF-H2O, 83%
TBDPSO
O O
O
OMe
1) O3, -78°C;
    Me2S, 80%
2) DIBALH, 0°C
3) Ac2O, pyr
    96% for 2 steps
4) AllylTMS
    BF3
.H2O
    4A-MS, 0°C
BnO
TBDPSO
O O
OMe
O
HO
O O
O
OMe
TBDPSO
O O
O
OMe
1) K2OsO4.2H2O
    (DHQ)2PHAL
    K3Fe(CN)6, K2CO3
    96%, 1:3.6 alpha:beta
2) Triphosgene
    Et3N, 72%
3) TBAF, 92%
O
O
O
1) CrO3, H2SO4    
    acetone
2) (PhO)2P(O)N3
    Et3N, 2-(TMS)EtOH 
    4A-MS, 65°C
    70% for 2 steps
H
N
O O
O
OMe
O
O
TMS
1) LiOH.H2O, MeOH, 76%
2) TBDMSCl, DMAP
    Et3N, 100%
3) CF3SO3Me
    2,6-(t-Bu)2-4-methylpyr
    70°C, 66%
O
O
O
H
N
O O
O
OMe
OMe
O
O
TMS
OTBDMS
TiCl4
71
72 73
74
75
76  
 
28 
  The reaction sequence was shorter than the previous two by Kishi and Nakata, requiring 
twenty-seven steps from the starting alkene, and utilized the innovative oxypalladation step.  
However, the selectivity of the side chain dihydroxylation of 75 was low. 
More recently, they have proposed an isoxazoline intermediate for 12-epi-mycalamide A, 
but a complete synthesis was not presented. 40 
In the late 1990s, Kocienski published several papers concerning mycalamide B.41  Their 
most recent synthesis began with the dihydropyranone 77.42  The first seven steps yielded the 
isopropylidene acetal 78 in 53% overall yield, which was then transformed into the terminal 
alkene 79 (Figure 29). 
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 Figure 29  Kocienski’s Amido Trioxadecalin Ring Synthesis – Part I 
O
O
Cl
CuBr.SMe2, THF
-70 to -30°C, 100%
O
O
Cl
SiMe2(O-iPr)
H2O2, KF
.2H2O
      KHCO3
O
OTBDMS
Cl
OTBDMS
1) TBDMSCl, Et3N 
    DMAP, CH2Cl2 
    RT, 94%
2) TBDMSOTf, Et3N
    CH2Cl2, RT, 100%
O
O
Cl
OH
Oxone, KHCO3, 18-c-6
PhMe-MeOH-H2O
0°C, 99%
O
OTBDMS
Cl
OTBDMS
O
PPTS, MeOH-H2O
O
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To complete the synthesis, the side chain was constructed, followed by formation of the 
trioxadecalin ring system of 80 by reaction with formalin. 
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 Figure 30  Kocienski’s Amido Trioxadecalin Ring Synthesis – Part II 
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A major advantage of this synthesis is how efficiently the dioxane ring was constructed 
(93% yield).  Also, the functionality of the side chain can be varied to produce artificial analogs 
of the mycalamides. Although the yields are quite good, a shorter synthesis is desirable. 
Marron and Roush developed a highly diastereoselective method for making the right 
half of mycalamide using the D-mannitol derived starting material 81.43 
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 Figure 31  Marron and Roush’s Amido Trioxadecalin Ring Synthesis – Part I 
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    65% for 3 steps
TMS B O
O
CO2Et
CO2Et
4A-MS, 93%
1) DMDO;
    MeOH-HOAc
    23°C, 89%
2) Ti(Oi-Pr)4, (-)-DIPT
    TBHP, CH2Cl2
    -20°C, 87%
B
O
O
CO2i-Pr
CO2i-Pr
82, PhMe
-78°C, 79%
O
O
O
TrocO
OMe
OH
HO
O
O
O
O
TrocO
OMe
OH
TMS
O
O
O
TrocO
OMe
O
O
O
O
HO
OMe
O O
HO
OMe
O O
O
HO
OMe
O O
OMe
O O
O
OH
O O
O
O O
83, PhMe, -78°C
82 83
OH
OH
OH
OH
HO
OH
81
 
 
 
 
32 
 Reaction of 84 with zinc in acetic acid resulted in formation of one of the rings, and 
reaction of 85 with phosphorous pentoxide and methylal produced the trioxadecalin ring system 
of 86.  Curtius rearrangement of the carboxylic acid 86 formed the carbamate 87 with (S)-
stereochemistry at C10 as the only isomer. 
Figure 32  Marron and Roush’s Amido Trioxadecalin Ring Synthesis – Part II 
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The most important part of this work was that it demonstrated stereocontrol at the N-acyl 
aminal carbon.  In addition, use of the boronate reagents 82 and 83 provided very good control of 
the stereochemistry.  This synthesis was again quite lengthy, consisting of twenty-three steps 
from the D-glyceraldehyde 3-pentylidene ketal starting material 81. 
Hoffmann made the trioxadecalin ring system of mycalamide B using sugars as the chiral 
starting material.  The group’s first approach involved L-xylose.44  Their most recent synthesis 
33 
 began with an acetal-protected D-arabinose 88, which contained three properly configured 
stereogenic centers (Figure 33).45 
Figure 33  Hoffmann’s Amido Trioxadecalin Ring Synthesis 
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The high stereoselectivity of the allylation of 89 was possible because the trioxadecalin ring 
system prefers the cis-conformation due to gauche effects, as described in the reference.  At the 
34 
 time this paper was published, this approach was the shortest synthesis of the trioxadecalin ring 
system, requiring only fifteen steps from the thioacetal.  The dihydroxylation of 90 did not give 
very high diastereoselectivity.  
Rawal’s total synthesis of mycalamide A reported a scheme using diethyl D-tartrate 91 as 
the starting material.26  The first ring was formed through a Lewis acid catalyzed cyclization to 
form 92, and the second by formylating the deprotected hydroxyl groups.  Sharpless 
dihydroxylation of 93 was used to functionalize the side chain. 
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 Figure 34  Rawal’s Amido Trioxadecalin Ring Synthesis 
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Overall, the synthesis required twenty-one steps with a 10.5% overall yield, and efficient 
stereoselective reactions were used. 
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 8. Synthesis: Psymberin – Right Fragment 
The structure of the right half of psymberin is shown in Figure 35. 
Figure 35  Psymberin - Right Fragment 
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O
OH
OH O
OH
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The two published syntheses of this fragment are described below. 
 
The right side of psymberin was prepared by De Brabander by first making the fragment 
in two parts.28  The first molecule was constructed from aldehyde 94 starting with Leighton’s 
allylsilane 95 in two consecutive steps (Figure 36). 
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 Figure 36  De Brabander’s Psymberin - Right Fragment Synthesis – Part I 
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Next, the terminal portion of psymberin was made from the dimethoxy-substituted benzaldehyde 
97 (Figure 37). 
Figure 37  De Brabander’s Psymberin - Right Fragment Synthesis – Part II 
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    NaIO4, MeOH-H2O
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The fragments were connected using a coupling method shown in Figure 38 to form the right 
fragment of psymberin. 
 
 Figure 38  De Brabander’s Psymberin - Right Fragment Synthesis – Part III 
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De Brabander’s scheme proceeded with very good stereoselectivity in 17 steps. 
In the same year, Floreancig et. al. published a synthesis of the N7 to C25 fragment of 
psymberin.46  The construction of the aryl ring included a cycloaddition with allene 
dicarboxylate 98 and a silylketene acetal 99.  The C16-C17 stereocenters were established 
through a Brown crotylation reaction of 100, as shown in Figure 39. 
 
 
 
 
 
 
39 
 Figure 39  Floreancig’s Psymberin - Right Fragment Synthesis – Part I 
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Allylation of 101 with Leighton’s allylsilane 102 was the key step in forming the fragment in 
Figure 40. 
Figure 40  Floreancig’s Psymberin - Right Fragment Synthesis – Part II 
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102101
 
These fragments were coupled using a Mukaiyama aldol reaction to form 103.  Following 
cyanation of 104, the intermediate was converted to the amide 105 using the Parkin catalyst 
(Figure 41). 
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 Figure 41  Floreancig’s Psymberin - Right Fragment Synthesis – Part III 
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Although the 6:1 diastereoselectivity of the Mukaiyama reaction was lower than De Brabander’s 
12:1, this approach to the right half was shorter than the previous one, requiring only fifteen total 
steps.  Also, the 15% overall yield was higher than the 8.9% reported by De Brabander. 
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 9. Synthesis: Fragment Coupling/Synthesis Completion 
One of the most important steps in the synthesis of pederin compounds is the coupling of 
the various fragments.  Several strategies have been proposed and are summarized in this section. 
 
Pederin 
After divulging a unique coupling method in previous papers,47 Matsumoto completed 
the first total synthesis of pederin using a methyl imidate.10  The amide was first converted to the 
N-(1-methoxyalkyl)amide 106 using trimethyloxonium tetrafluoroborate (Figure 42). 
Figure 42  Matsumoto’s Pederin Coupling – Part I 
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Also, the pederic acid fragment was converted to the acid chloride 107 using thionyl chloride 
(Figure 43). 
Figure 43  Matsumoto’s Pederin Coupling – Part II 
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 The two intermediates were then coupled using the method shown in Figure 44. 
 
 
 
 
42 
 Figure 44  Matsumoto’s Pederin Coupling – Part III 
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This coupling was a pioneering step in pederin synthesis; however, the desired product 108 was 
present in a 2:7 ratio with the epi-analog.  The ratio was improved using kinetically controlled 
alkoxy exchange reactions to increase the proportion of the preferred product, as described in the 
paper. 
Employing a similar method, Kocienski coupled the two fragments of pederin via the N-
acylimidate 109 derived from the amide shown in Figure 45.11d  Subsequent coupling with the 
metallated dihydropyran 110 and formation of the 4-methylene group through removal of the 
phenylselenium group of 112 yielded the final pederin product 113.  This coupling method was 
also used by Kocienski for mycalamide coupling. 
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 Figure 45  Kocienski’s Pederin Coupling 
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44 
 A key step here is the rhodium catalyzed hydroboration of the imidate 109, which 
stereoselectively forms the desired C10 configuration with a much higher 10:1 diastereomeric 
ratio.  Diastereoselectivity of the addition of methanol at C6 of 111 was very high as well 
(>20:1).  The reduction of the C7 carbonyl of 111 was not as successful, yielding the desired 
product in only a 3:1 ratio. 
 
Psymberin 
De Brabander’s group presented a coupling strategy for psymberin using the three 
fragments that were constructed previously.28  The acid chloride 115 was prepared from 
protected psymberic acid using oxalyl chloride.  Their approach is shown in Figure 46. 
Figure 46  De Brabander’s Psymberin Coupling 
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    PhMe, 40°C;
    NaBH4, EtOH, 0°C
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The final product of this synthesis was used to establish that psymberin and irciniastatin are 
identical compounds.  A higher diastereoselectivity of the coupling reaction of 114 and 115 
would be an improvement on this work. 
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 Mycalamides 
Kishi coupled a tosyl pederic acid derivative 116 with the amino trioxadecalin ring 
system 117 to make a mixture of diastereomers, which were converted to the desired epimer 
using a basic equilibrium as shown in Figure 47.36 
Figure 47  Kishi’s Mycalamide Coupling 
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A milestone of this work was the establishment of the absolute configuration of 
mycalamides A and B using enantioselective synthesis (mycalamide B was synthesized using 
different protection of the side chain hydroxyls, as described in the paper).  The 78% yield for 
this coupling was very good, and the approach was simple.  However, there was very little 
diastereoselectivity for the reaction. 
Hoffmann proposed a novel approach to coupling using an isocyanate analog of the 
trioxadecalin portion of the molecule as a model (Figure 48).48  Unexpectedly, deprotection of 
the SEM group of 119 also reduced the C7 carbonyl to the hydroxyl group.  The authors 
speculate that this reduction may be caused by a methoxylate anion generated during the 
deprotection. 
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 Figure 48  Hoffmann’s Mycalamide Coupling 
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Although the 87% yield for this method is quite high, the 1:1 diastereoselectivity is poor. 
As mentioned earlier, Kocienski used the metallated dihydropyran approach from his 
pederin synthesis to form 18-o-methyl mycalamide B.40a  The azido trioxadecalin ring system 
120 was converted to the N-acyl aminal 121 before coupling (Figure 49). 
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 Figure 49  Kocienski’s Mycalamide Coupling 
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This C18 methylated analog 123 showed similar anti-tumor activity to the naturally occurring 
mycalamides A and B against various carcinoma cell lines. 
Kocienski’s work provided a unique approach to mycalamide coupling, and the yield is 
reasonably good.  Due to the poor stereoselectivity of several steps in this reaction scheme, 
though, the four stereoisomers present following reduction of the C7 ketone required separation. 
48 
 To couple the mycalamide fragments, Rawal used a classic DCC coupling method with 
DMAP as a catalyst (Figure 50).26  The desired 10-(S) configuration of 124 was obtained in a 5:1 
ratio. 
Figure 50  Rawal’s Mycalamide Coupling 
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This approach to mycalamide coupling is very appealing due to its simplicity and good 
stereoselectivity. 
 
10. Analogs 
As can be seen from the examples above, synthesis of pederin and the mycalamides 
involves lengthy and challenging strategies.  In an attempt to determine what regions of these 
molecules are responsible for pederin bioactivity, many synthetic analogs have been made by 
either treating the original compounds with various reagents or synthesizing them from simple 
starting materials.  These experiments have provided some insight toward designing artificial 
analogs with the same anti-tumor and immunosuppressive properties as the pederin cytotoxins. 
Munro et. al. systematically transformed the mycalamides into non-natural analogs using 
various reagents.49 Among the treatments were acylation, alkylation, silylation, hydrolysis, 
oxidation, and reduction.  These compounds were then tested for in vitro cytotoxicity against 
P388 leukemia cells, and relevant results are discussed below. 
49 
 Additionally, analogs were synthesized by several researchers.  These experiments also 
provided some insight into structure-activity relationships of the pederin family.  For clarity, the 
results of this research will be discussed by position along the molecule. 
The O1-C6 pederic acid portion of the molecule will be considered first (Figure 51). 
Figure 51  O1-C6 Fragment of Pederin 
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 No variations of the C1 and C2 positions have been studied to date.  As for the C3 
position, Nakata et. al. concluded that the methyl substituent is not important in analogs of 
mycalamide;50 however, a recent study by this group suggests that the C3 position may in fact be 
significant for biological effectiveness against HeLa cells.51  When a C3-C4 double bond was 
introduced, the compound was 100 times less efficacious.  The C4 exo-methylene group 
therefore shows some significance. 
When reduced to the 4β-methyl analog, the cytotoxicity of mycalamide A more than 
doubled (no change was observed for mycalamide B).  However, the α isomers were 4-8 times 
less active than the natural compounds.49c 
No data have been collected for C5 variations, likely due to the lack of substitution at that 
position.  Notably, conversion of the C6 acetal to a hydroxyl results in a 20-40 fold loss in 
effectiveness.  
The C7-N9 amide portion connecting the left and right fragments was studied by several 
groups (Figure 52). 
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 Figure 52  C7-N9 Fragment of Pederin 
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A consistent finding was that this α-hydroxy amido group is critical for cytotoxicity, as 
shown by the 1000 fold reduction in activity when the 7-hydroxy group and the amide nitrogen 
were methylated.  The efficacy was reduced 100 fold when the 7-hydroxyl alone was methylated.  
Also, when the molecule was cleaved between C7 and C8, and each half of the molecule was 
tested separately, cytotoxicity was orders of magnitude less than the parent molecule (800 ng/mL 
for the left half 125, 110 ng/mL for the right half 126), suggesting that both segments shown in 
Figure 53 are involved in the bioactivity. 
Figure 53  Pederin Fragments for Bioactivity Study 
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The C10-C15 portion of the trioxadecalin ring system, shown in Figure 54, also shows 
some notable findings. 
Figure 54  Trioxadecalin Ring System 
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 The C10 acetal is important, as conversion to the hydroxy significantly reduced the IC50 
value.  The (S) configuration at C10 is also important for cytotoxicity, as the R epimer of 
mycalamide B showed a pronounced reduction in activity. 
Modification of the side chain revealed some interesting data.  Ruthenium catalyzed 
oxidation of mycalamide B introduced a C16-C17 double bond and simultaneous elimination of 
C18 yielded normycalamide B (Figure 55). 
Figure 55  Normycalamide B 
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This product was a much less effective cytotoxin than mycalamide B.49c  This 100 fold reduction 
in activity implies that the side chain may play a role in this molecule’s bioactivity.  However, 
the lower activity may be the result of the instability of this molecule. 
A methoxy group at C17 is much better than a hydroxy substituent, as demonstrated by 
comparison of the natural mycalamides A and B.  Oxidation of the side chain yielded various 
side products, including a terminal C17 aldehyde and terminal C17 alcohol.  Both were more 
active than mycalamide A.  Methylation of the 18-hydroxy improves the toxicity of mycalamide 
B to the same level as pederin. 
 Overall, the amide functionality appears to play the most important role in the biological 
activity of these compounds.  These studies show promise for the design of a pederin analog that 
will ideally be as biologically active, yet be produced through a shorter, more efficient synthesis. 
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 11. Conclusion 
Since its discovery, pederin and its relatives have been the subject of a significant amount 
of research.  Their unique cytotoxic properties have spurred a great deal of synthetic research of 
pederin, the mycalamides, and more recently psymberin.   
Ultimately, cloning of the symbiont itself would be the most efficient method of 
producing these cytotoxins.  Continued work may one day make this option a reality, but for now 
syntheses like those presented above are the most viable approach. 
A great deal has been learned about the structure-property relationships through 
modification of the mycalamides and synthesis of analogs.  Continued research of these 
molecules and their analogs may potentially lead to advancement in the treatment of cancer.   
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APPENDIX A 
 
 
 
Chemical Acronyms 
 
 
Am   amyl 
BOC-ON  2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile 
Bn   benzyl       
Bz   benzoyl 
m-CPBA  meta-chloroperbenzoic acid 
CSA   camphorsulfonic acid 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC   dicyclohexylcarbodiimide 
DDQ   2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DHQ)2PYR  1,4-bis(dihydroquinidyl)benzo[g]phthalazine 
DIAD   diisopropylazodicarboxylate 
DIBALH  diisobutyl aluminum hydride 
DIPT   diisopropyl tartrate 
DMAP   4-dimethylaminopyridine 
DMDO  dimethyldioxirane 
DMF   dimethylformamide 
DMPM  3,4-dimethoxyphenylmethyl 
DMPU   1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone 
DMSO   dimethylsulfoxide 
EDC   1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
HMPA   hexamethylphosphoramide 
HOBt   1-hydroxybenzotriazole 
Ipc   isopinocamphenyl 
KHMDS  potassium hexamethyldisilazane 
LAH   lithium aluminum hydride 
LDA   lithium diisopropylamide 
MPM   p-methoxyphenylmethyl 
MS   molecular sieve 
Ms   methanesulfonyl 
NIS   N-iodosuccinimide 
NMO   N-methylmorpholine-N-oxide 
PCC   pyridinium chlorochromate 
PDC   pyridinium dichromate 
PPTS   pyridinium p-toluenesulfonate 
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 PyBOP  benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate 
SEM   2-(trimethylsilyl)ethoxymethyl 
TASF   tris-(diethylamino)sulfonium difluorotrimethyl silicate 
TBAF   tetrabutylammonium fluoride 
TBDMS  t-butyldimethylsilyl 
TBDPS  t-butyldiphenylsilyl 
TBHP   t-butylhydroperoxide 
THF   tetrahydrofuran 
THP   tetrahydropyranyl 
TMEDA  tetramethylethylenediamine 
TMS   tetramethylsilyl 
Tr   trityl, triphenylmethyl 
Troc   2,2,2-trichloroethoxycarbonyl 
WSC   [1-(3-(dimethylamino)propyl)]-3-ethylcarbodiimide hydrochloride 
55 
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